leadf
logo-loader
viewCreso Pharma Ltd

Creso Pharma set to capitalise on near-term opportunities after United Nations reclassifies cannabis as less dangerous drug

The decision, in essence, recognises the potential medical properties of cannabis and paves the way for the relaxing of cannabis classifications in large markets across the world.

Creso Pharma Ltd - Creso Pharma set to capitalise on near term opportunities after United Nations reclassifies cannabis as less dangerous drug
The decision is expected to have major impacts on the global cannabis industry

Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) is ready to capitalise on a number of near-term opportunities that will materialise after the United Nations Commission on Narcotic Drugs’ landmark decision to reclassify cannabis as a Schedule 1 substance, which is the least restrictive drug classification. 

The company said the decision to withdraw cannabis from the most dangerous and addictive drugs Schedule IV classification of the 1961 Drug Convention Treaty, signalled a significant global trend toward the relaxation of access to cannabis. 

This decision, in essence, recognises the potential medical properties of cannabis and paves the way for the relaxing of cannabis classifications in large markets across the world.

Landmark decision

Creso Pharma co-founder and director Boaz Wachtel said: “The UN ruling to reclassify cannabis is a landmark decision and paves the way for the relaxing of cannabis drug classifications in large markets across the world.

“The result of this vote follows 60 years of status quo, three years of scientific review by the world’s leading health organisations, two years of diplomatic discussions and considerable lobbying from NGOs.

“I am proud and privileged to have been a part of a small group of dedicated activists that have fought for decades to reschedule cannabis.

I am very confident that this decision will unlock a number of near term opportunities for Creso Pharma, and I look forward to working with the board and management to unlock further value for shareholders.”

Shares have been as much as 32% higher to A$0.083 intra-day.

Commission on Narcotic Drugs

A vote to reschedule cannabis took place on December 2, 2020, and was undertaken by the Vienna-based Commission on Narcotic Drugs (CND) which has 53 member states.

The CND reviewed a series of World Health Organisation (WHO) recommendations on reclassifying cannabis and its derivatives ahead of the vote.

Wachtel was part of the European Coalition for Just and Effective Drug Policies, which was involved in driving the change in the classification of cannabis.

He attended a number of UN Drug Convention meetings in Vienna and assisted in writing and coordinating research papers that were submitted to the CND ahead of the vote.

This participation also saw him liaise with some of the 250 non-government organisations that signed a petition on the reclassification of cannabis.

Well-funded to pursue growth initiatives

The decision is expected to have major impacts on the global cannabis industry.

Creso Pharma anticipates a number of near-term opportunities will materialise as a result of the ruling, including opportunities that the company was unable to previously pursue.

It intends to capitalise on these opportunities immediately.

Creso has an established global footprint and is well-funded to pursue multiple growth initiatives.

Quick facts: Creso Pharma Ltd

Price: 0.23 AUD

ASX:CPH
Market: ASX
Market Cap: $209.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 11/6/20

3 min read